Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency
Journal of Thrombosis and Haemostasis · 2023-03 · 21 (3) · 467-479
DOI: 10.1016/j.jtha.2022.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-03. Verfasst von Stéphanie E Reitsma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Factor XI Deficiency. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, Novo Nordisk.
Abstract (Originalsprache)
BACKGROUND: Factor (F) XI deficiency is associated with increased bleeding risk in some individuals. Neither FXI levels nor clinical clotting assays predict the bleeding risk. Compared with controls, FXI-deficient bleeders have reduced clot formation, decreased fibrin network density, and increased susceptibility to fibrinolysis. Tissue factor pathway inhibitor (TFPI) was recently implicated as a modifying factor in individuals with bleeding of unknown cause. OBJECTIVES: To determine the potential of TFPI in modifying the bleeding risk in FXI-deficient individuals. METHODS: The effects of TFPI on thrombin generation and clot formation, structure, and fibrinolysis in FXI-deficient plasma were measured in vitro in the absence or presence of inhibitory anti-TFPI antibody or exogenous recombinant TFPIα. Total plasma TFPI concentration was measured in 2 independent cohorts of controls and FXI-deficient individuals classified as bleeders or nonbleeders (cohort 1: 10 controls and 16 FXI-deficient individuals; cohort 2: 48 controls and 57 FXI-deficient individuals) and correlated with ex vivo plasma clot formation and fibrinolysis parameters associated with bleeding risk. RESULTS: In an in vitro FXI deficiency model, inhibition of TFPI enhanced thrombin generation and clot formation, increased the network density, and decreased fibrinolysis, whereas an increase in TFPI had the opposite effects. Compared with controls, plasma from FXI-deficient bleeders had higher TFPI concentration. Total plasma TFPI concentrations correlated with parameters from ex vivo clotting and fibrinolysis assays that differentiate FXI-deficient bleeders and nonbleeders. CONCLUSION: Coagulation and fibrinolysis parameters that differentiate FXI-deficient nonbleeders and bleeders were altered by plasma TFPIα. Total plasma TFPI was increased in FXI-deficient bleeders. TFPI may modify the bleeding risk in FXI-deficient individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina, Chapel Hill, North Carolina, USA.
- Department of Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill, North Carolina, USA.
- Versiti Blood Research Institute, Milwaukee, Wisconsin, USA.
- Department of Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK; Institute of Cancer Sciences, The University of Manchester, Manchester, UK.
- Institute of Cardiovascular Sciences, The University of Manchester, Manchester, UK.
- Institute of Cancer Sciences, The University of Manchester, Manchester, UK; Department of Haematology, St James' Hospital, Leeds Teaching Hospitals Trust, UK.
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- Novo Nordisk
- National Institutes of Health
Zitieren
APA
Reitsma, S. E., Holle, L. A., Bouck, E. G., Monroe, D. M., Mast, A. E., Burthem, J., Bolton-Maggs, P. H. B., Gidley, G. N., & Wolberg, A. S. (2023). Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency. Journal of Thrombosis and Haemostasis, 21(3), 467-479. https://doi.org/10.1016/j.jtha.2022.10.005
Vancouver
Reitsma SE, Holle LA, Bouck EG, Monroe DM, Mast AE, Burthem J, et al. Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency. Journal of Thrombosis and Haemostasis. 2023;21(3):467-479. doi:10.1016/j.jtha.2022.10.005
BibTeX
@article{Reitsma2023,
author = {Reitsma, Stéphanie E and Holle, Lori A and Bouck, Emma G and Monroe, Dougald M and Mast, Alan E and Burthem, John and Bolton-Maggs, Paula H B and Gidley, Gillian N and Wolberg, Alisa S},
title = {Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency},
journal = {Journal of Thrombosis and Haemostasis},
year = {2023},
volume = {21},
number = {3},
pages = {467--479},
doi = {10.1016/j.jtha.2022.10.005}
}
EUVIMED